Edelfosine was the first antitumor drug reported to promote an apoptotic response through FasL/CD95L-independent activation of Fas/CD95 by its recruitment in lipid rafts [1], linking for the first time membrane rafts and Fas/CD95-mediated apoptosis in cancer chemotherapy. Here, FAS is linked to cancer.